What Is the Real Success Rate of Stem Cell Therapy? An Honest 2026 Guide

Why "success rate" is the wrong question

Every consultation eventually arrives at the same question. *What is the success rate of stem cell therapy?* It is a reasonable thing to ask. It is also, for most regenerative indications, a question that hides more than it reveals.

The reason is that "success" is not a fixed concept in regenerative medicine. It depends on what is being measured, who is being measured, when the measurement is taken, what counts as a clinically meaningful improvement, and whether the comparison group is no treatment, conventional treatment, or placebo. A clinic that quotes "90 percent success" without specifying any of those parameters is quoting a number that cannot be evaluated. A more useful starting point is to replace "success rate" with two more precise ideas: the *responder rate* (what proportion of patients with this condition meet a defined threshold of improvement) and the *magnitude of response* (how much the responders improved on validated outcome scales).

Both numbers come from the published clinical literature and from our own outcomes tracking. Neither is a guarantee for any individual patient, and any decision about stem cell therapy should be made with your treating physician after a full evaluation. What follows is an honest attempt to lay out what those numbers actually look like across the conditions patients most commonly ask about, and the framework we use at Regeneris to set realistic expectations.

How to interpret outcome numbers

Before any specific percentages are useful, three pieces of context are necessary, because almost every misleading "success rate" claim in this field comes from omitting one of them.

The first is the threshold. When a study or a clinic says "60 percent of patients improved," the next question is always: improved by how much? The standard in joint osteoarthritis is the WOMAC (Western Ontario and McMaster Universities Osteoarthritis Index), and the conventional threshold for a *minimum clinically important difference* is roughly a 30 percent reduction from baseline. So "60 percent of patients improved" without a threshold could mean "60 percent reported any change" — a much weaker statement than "60 percent reduced their WOMAC by at least 30 percent." Always ask which threshold is being used.

The second is the timing. The same protocol can have a 50 percent responder rate at 6 weeks and a 70 percent responder rate at 6 months, because the biology of cell-based therapy unfolds over time. Quoting the most flattering time point without noting the curve is a common pattern in clinic marketing.

The third is the patient selection. A clinic that treats only mild-to-moderate disease in otherwise healthy patients will report different numbers than a clinic that treats end-stage disease in patients with multiple comorbidities. Without knowing who was treated, the success rate is not comparable across clinics. Our how to choose a stem cell clinic guide covers what to ask about patient selection in more detail.

A useful frame is the *responder vs non-responder* split. Across most regenerative indications, the published literature describes a population that divides into roughly three groups: clear responders who experience meaningful improvement on validated scales, partial responders who experience some improvement that may or may not cross the clinical threshold, and non-responders who do not measurably benefit. The clinically interesting number is the proportion of clear responders, not "everyone who said they felt a little better."

Success rates by condition

The numbers below are typical ranges drawn from the published clinical literature on MSC therapy and from our own outcomes tracking at Regeneris. They are not promises, and individual results vary substantially within each range. Each row reflects the proportion of patients who meet a clinically meaningful improvement threshold on a named validated scale at the typical follow-up window for that indication.

| Condition | Typical responder rate | Validated outcome measure | |---|---|---| | Knee osteoarthritis | 60-75% with at least 30% pain reduction at 6 months | WOMAC, VAS | | Lumbar disc disease | 50-65% with at least 30% pain reduction at 6 months | ODI, VAS | | Fibromyalgia | 40-55% with meaningful FIQ improvement at 6 months | FIQ, FIQR | | Lupus (SLE) | 50-60% with SLEDAI improvement at 6-12 months | SLEDAI, anti-dsDNA | | Multiple sclerosis (relapsing-remitting) | 40-60% relapse rate reduction at 12 months | Relapse count, MRI, EDSS | | Erectile dysfunction | 50-65% with meaningful IIEF-5 improvement at 6 months | IIEF-5, patient-reported | | Hair restoration (early-moderate AGA) | 60-75% with perceived density improvement at 9-12 months | Standardized photography, questionnaires | | Anti-aging biomarker protocols | 50-70% with improvement on selected biomarkers at 6 months | Inflammatory markers, immune panel | | Long COVID symptoms (emerging data) | 40-60% with symptom-burden reduction at 6 months | Patient-reported, fatigue scales |

A few notes on this table, because every row hides nuance that the row itself cannot show.

For knee osteoarthritis, the 60 to 75 percent responder rate applies most cleanly to Kellgren-Lawrence grade II-III disease. Grade IV (bone-on-bone) patients respond at lower rates, and for that group surgical replacement is often the more durable option. Our deep dive on stem cells for knee osteoarthritis walks through the staging logic.

For lumbar disc disease, the 50 to 65 percent range applies to contained disc herniations and discogenic pain, not to sequestered fragments with neurologic compromise, which are surgical questions. The stem cells for lumbar disc herniation post is the more detailed companion.

For autoimmune indications (lupus, MS, fibromyalgia), the timeline is longer and the outcome instruments are different from joint disease. Patients should expect to see lab marker shifts before they feel clinical change, often by two to three months. Continued evidence-based disease-modifying therapy alongside regenerative care, managed by the patient's existing specialist, is part of why responders maintain results.

For ED, the responder rate depends heavily on the underlying etiology. Vascular-origin ED in patients without severe diabetes responds at the upper end of the range; post-radical-prostatectomy nerve injury and advanced vascular disease respond at the lower end.

For anti-aging protocols, the 50 to 70 percent figure is for *biomarker improvement on the panel being measured*, not for the harder claim of "biological age reversal." The published evidence base for stem cell therapy as a longevity intervention is much weaker than for the disease-specific indications, and our anti-aging longevity overview is honest about that gap.

For long COVID, the data is emerging and the responder ranges should be treated as preliminary. We treat this carefully and only after a full evaluation; our stem cells for long COVID post discusses what is and is not known.

Why some patients don't respond

A more useful question than "what is the success rate" is "what makes someone a non-responder." Five factors recur across the literature and across our own clinical experience, and they are part of every honest pre-treatment conversation.

Disease severity at treatment. End-stage disease — Kellgren-Lawrence IV knee osteoarthritis, severely sequestered disc fragments, advanced fibrotic changes — responds less reliably than earlier-stage disease. Cells signal to tissue that can still respond; tissue that has structurally failed cannot be regrown by signaling alone.

Comorbidities. Uncontrolled diabetes, severe obesity, active autoimmune disease beyond the target indication, ongoing infection, recent or active cancer, and chronic high-dose immunosuppression all reduce the responder rate. These are biological realities, not judgments. A thorough baseline workup that surfaces these issues lets us either optimize them first or set expectations honestly.

Timing. Acute injuries within a defined window often respond better than chronic problems that have been present for years. For chronic indications, however, "too early" is rarely the issue; "too late" is more common, particularly for joint disease that has progressed to structural failure.

Expectations. Patients who expect a one-time cure for a chronic condition often perceive themselves as non-responders even when objective measures show meaningful improvement, because the improvement was real but partial. Realistic expectations are not a placebo trick; they are how patients accurately interpret what is happening in their own bodies.

Dose, route, and product quality. Underdosed protocols, suboptimal routes for the indication, or products without proper characterization respond at lower rates. This is part of why clinic selection matters; our clinic safety guide for Mexico covers what to verify.

How to maximize your chances

The factors that move a patient toward the responder side of the curve are mostly the same ones that extend durability, which our stem cell results timeline covers in detail. Briefly, they include:

• Eligibility screening. A clinic that takes "no" seriously — that declines to treat patients whose underlying biology or disease stage is unlikely to respond — is one whose published responder rates are more meaningful. A clinic that treats everyone treats some patients whose expectations cannot be met.
• Lifestyle optimization. Smoking cessation, weight management when relevant, sleep regularization, structured exercise, and management of metabolic comorbidities all push the responder probability upward. These are not optional add-ons; they are part of the protocol.
• Adjunct therapies. PRP, peptides, IV nutrition, physical therapy where appropriate, and structured rehabilitation extend and amplify what cell therapy can do. Our combining stem cells with PRP and peptides post discusses the synergies in more detail.
• Dose adequacy. Underdosed protocols are cheaper but show lower responder rates. The right dose depends on the indication, the source (autologous vs allogeneic), and the cell type. Our autologous vs allogeneic stem cells post lays out the choices.
• Follow-up engagement. Patients who attend follow-up visits, report symptoms honestly, and participate in measurement on validated scales get better calibrated care. Patients who disappear after the procedure cannot benefit from adjustments to their plan.

What we measure at Regeneris

A responder rate is only meaningful if the measurement is consistent, validated, and applied at defined time points. The instruments we use map directly to the published clinical literature in each indication, because that is the only way to compare outcomes honestly.

For joint disease: WOMAC (knee and hip osteoarthritis), Oxford Knee Score where appropriate, visual analog pain scores, and functional measures including walking distance, range of motion, and stair tests, recorded at baseline and at 3, 6, and 12 months, with imaging at baseline and 12 months when clinically warranted.

For spine: ODI (Oswestry Disability Index), VAS pain scores, neurologic examination, and imaging at appropriate intervals.

For autoimmune disease: SLEDAI for lupus, FIQ and FIQR for fibromyalgia, tailored quality-of-life instruments for multiple sclerosis and Hashimoto's thyroiditis, alongside disease-specific lab markers (anti-dsDNA, complement, inflammatory markers, thyroid antibodies, ESR, CRP) at protocol-appropriate intervals.

For ED: IIEF-5 and patient-reported outcome measures.

For hair restoration: standardized photography under fixed lighting at baseline and at 4, 6, 9, and 12 months, along with patient questionnaires.

For anti-aging protocols: inflammatory markers, immune function panels, and where appropriate metabolic markers, with the caveat that biomarker change is not the same as the harder longevity claims sometimes attached to this category.

This documentation supports two things at once. For the individual patient, it makes the conversation about whether a top-up dose makes sense — covered in our timeline post — a structured one rather than a guess. For our clinical learning, it lets us honestly assess what our actual responder rates look like over time, which is the only basis on which a clinic can quote numbers that mean anything.

When "success" doesn't equal "cure"

A regenerative response is not the same thing as a cure, and the distinction matters more than any percentage. For most of the conditions we treat — knee osteoarthritis, lumbar disc disease, autoimmune presentations — the underlying drivers continue to apply biological pressure after treatment. Cartilage continues to face mechanical load. Immune dysregulation continues to have whatever upstream drivers caused it. Vascular disease continues to progress at whatever rate the patient's overall risk profile dictates.

What stem cell therapy can do is meaningfully reduce the symptom burden, slow progression, modulate inflammation, and give patients functional months or years they would not otherwise have. That is a real outcome with real value, and it shows up consistently in the responder data. It is not the same as making the disease go away.

This is why our outcomes language emphasizes *responder rate*, *magnitude of improvement on validated scales*, and *durability of effect* rather than "cure rate." A clinic that uses "cure" routinely in marketing material for chronic disease is misaligning its language with what the science supports. Our FDA vs COFEPRIS guide discusses how "approved" gets similarly stretched in this space.

Red flags in clinic-published success numbers

If you encounter "success rate" claims while researching clinics, a small number of red flags repeat across the field. Recognizing them protects you from numbers that cannot be honestly evaluated.

• No threshold named. "90 percent of patients improved" with no specification of what counts as improvement. The improvement could be a one-point change on a ten-point scale.
• No outcome instrument named. Real outcomes are measured with WOMAC, ODI, SLEDAI, IIEF-5, FIQ, and similar validated scales. Marketing-only metrics ("most patients reported feeling better") are not the same.
• No time point named. A 90 percent rate at week 2 is a different claim than a 90 percent rate at month 12. Without the time point, the claim is unfalsifiable.
• No denominator named. Out of how many patients? With which condition? At which disease stage? A "90 percent success" calculated on the 30 patients the clinic remembered to follow up with is not the same as the 90 percent calculated on all 300 patients treated.
• No mention of non-responders or partial responders. A responsible clinic talks about all three groups. A clinic that mentions only success stories is curating.
• Guarantees of any kind on biologic therapy. Money-back, outcomes-guaranteed, or success-guaranteed language. No responsible provider offers any of these on cellular therapy.
• Universal claims across diverse indications. A clinic that quotes the same responder rate for knee osteoarthritis, MS, ED, and anti-aging is not distinguishing between biologically distinct problems.

A clinic that publishes numbers tied to specific outcome instruments, specific thresholds, specific time points, and named denominators — including their non-responders — is operating in a register that lets you actually evaluate what is being offered.

Realistic expectations setting

The most useful conversation we have with prospective patients during consultation is about realistic expectations specific to their case, not about a global success rate. We can describe the typical responder rate for a given condition, identify which factors in their history and biology may move them above or below the typical range, design a protocol with structured measurement, and be honest about what we can and cannot tell in advance.

A useful frame is to ask any clinic three things: what proportion of patients with my exact condition tend to respond meaningfully, what the typical magnitude and duration of response look like, and what next steps exist if I fall on the lower end. A clinic that can answer all three in concrete language, including the disappointing cases, is one practicing rather than selling. A clinic that gives you a single high number and changes the subject is not.

For a broader decision-stage overview, the considering stem cell therapy guide is the earlier-funnel companion to this post, and our stem cell information hub is the structured library. For documented outcomes from our practice — within the limits of patient privacy, and not curated to only the best cases — see our results page. For the more granular review of how protocols and packages are structured, see stem cell packages.

FAQ

What is the overall success rate of stem cell therapy? There is no single overall success rate, because "success" depends on the condition, the outcome instrument, the threshold, the time point, and the patient selection. A clinic that quotes a single global number is making a claim that cannot be evaluated. The honest answer is to look at responder rates by indication, on named validated scales, at defined follow-up windows — the numbers in the table above are a starting point.

Is a 60 to 75 percent responder rate for knee osteoarthritis "good"? It is broadly consistent with the published literature for MSC therapy in mild-to-moderate knee osteoarthritis, and it is meaningfully better than placebo response rates in the same condition. It is not a guarantee that any individual patient will respond; it is a population-level statistic. Patients with grade IV disease, severe comorbidities, or unmanaged contributing factors should expect lower responder probabilities than patients in better baseline shape.

If the responder rate is 60 percent, does that mean I have a 60 percent chance? Not exactly. Population responder rates are averages across patients with varying severity and comorbidities. Your personal probability depends on where you sit on those factors, which is what we work through in consultation. A patient with mild disease, no significant comorbidities, and a willingness to engage with lifestyle optimization typically sits above the population average; a patient with end-stage disease and multiple comorbidities typically sits below.

Why do some clinics claim 90 or 95 percent success? Either the threshold for "success" is set very low, the patient selection is curated, the measurement is informal or unstandardized, the time point is chosen to flatter, or the number is simply marketing. A real responder rate at 90+ percent on a validated scale would represent a substantial outlier from the published literature and would warrant skepticism, not enthusiasm.

What can I do to be in the responder group? The factors most under patient control are eligibility screening (be honest with the clinic about your full history so they can be honest about whether you are a good candidate), comorbidity management (particularly diabetes, obesity, and metabolic syndrome), lifestyle optimization (sleep, exercise, smoking cessation), and engagement with adjunct therapies and follow-up. None of these guarantee a response, but they meaningfully shift the probability.

Is partial response a failure? No. A patient who experiences a 20 to 25 percent improvement on a validated scale, even if it falls just below the conventional 30 percent threshold for "responder," has often had a clinically meaningful change in their day. Pain that is meaningfully reduced but not eliminated, function that is meaningfully improved but not fully restored — these are real outcomes. The threshold is a statistical convention, not the boundary of clinical value.

Closing thoughts

The realistic answer to "what is the success rate of stem cell therapy" is that meaningful responder rates by condition typically sit between 40 and 75 percent on validated outcome scales at six to twelve months, with substantial variation by disease stage, patient biology, dose, and adjunct care. A single global success number is not a serious answer; a structured set of responder rates by indication, on named instruments, at defined time points, with the non-responder cases acknowledged, is.

If you would like to discuss what realistic responder probabilities look like for your specific situation, you can request a regenerative consultation and we will walk through eligibility, expected response curves, and limits before any recommendation. You can also meet the physicians responsible for these decisions on our team page. Individual results vary, and any decision about stem cell therapy should be made with your treating physician.